US FDA Generic Drug Approvals, Other Actions Declined As Approval Times Climbed In FY 2024

 
• By Derrick Gingery
  
The FY 2024 generic drugs activity data likely will inform user fee reauthorization negotiations, which will begin in 2025. (Shutterstock)

More from Generics

More from Biosimilars & Generics